DGAP-Adhoc: Evotec AG announces its intent to acquire

Evotec AG  / Key word(s): Mergers & Acquisitions

26.10.2016 09:00

Disclosure of an inside information according to Article 17 MAR,
transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard,
ISIN: DE 000 566480 9, WKN 566480) today announced that it has made an
offer to acquire Cyprotex PLC (AIM Listing: CRX-GB), a specialist
pre-clinical contract research organisation in ADME-Tox and DMPK
headquartered in UK. The proposed acquisition, which has been unanimously
recommended by the board of Cyprotex, is expected to close before year-end
2016.

Evotec will pay approximately £ 55.36 m (EUR 62.00 m; £/EUR exchange rate
of 1.12) in cash for the acquisition of all 26.1 million issued and to be
issued Cyprotex shares and the funding of all existing company debt. The
offer of 1.60 £ per Cyprotex share reflects a 9.4% premium to the VWAP of
the past 30 trading days at AIM. The offer is intended to be implemented by
a scheme of arrangement regulated by the UK takeover code, with already
>50% shares secured irrevocable.


Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec AG, Manfred
Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49.(0)40.560
81-242, werner.lanthaler@evotec.com


26.10.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Evotec AG
              Manfred Eigen Campus / Essener Bogen 7
              22419 Hamburg
              Germany
Phone:        +49 (0)40 560 81-0
Fax:          +49 (0)40 560 81-222
E-mail:       info@evotec.com
Internet:     www.evotec.com
ISIN:         DE0005664809
WKN:          566480
Indices:      TecDAX
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated
              Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
              Munich, Stuttgart, Tradegate Exchange
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------
DGAP-Adhoc: Evotec AG announces its intent to acquire Cyprotex PLC
